Serious infections occurred in 23.4% of DLBCL patients treated with commercial CD19 CAR T cell products; nonetheless, most infections were manageable and infection-related mortality was low similar to the results of previous reports5,7,17. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.